Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment of metabolic diseases, today announced that (i) on October 20, 2025, one new employee was granted an inducement award consisting of a stock option to purchase 23,602 shares of common stock, (ii) on October 28, 2025, three new employees were granted inducement awards consisting of stock options to purchase an aggregate of 49,849 shares of common stock and (iii) on November 3, 2025, one new employee was granted an inducement award consisting of a stock option to purchase 14,766 shares of common stock.